2Steer CB, Szer J, Sasadeusz J, et al. Varicetla-zoster infection after allogeneic bone marrow transplantation, risk factors and prevention with low-dose-dose aciclovir and ganciclovir[ J ]. Bone Marrow Transplant, 2000,25 ( 6 ) : 657 - 664.
3McGavion JK, Gona KL. Ganciclovir : an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients [ J ]. Drugs, 2001,61 ( 8 ) : 1153 - 1183.
1[1]Faulds D, Heel RC. Ganciclovir. A review of its antiviral activity,pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections[J]. Drugs, 1990, 39(4): 597-638.
2[2]Markham A, Faulds D. Ganciclovir. An update of its therapeutic use in cytomegalovirus infection[J]. Drugs, 1994, 48(3): 455-484.
3[3]Koyano S, Suzutani T, Yoshida I, et al. Analysis of phosphorylation pathways of antiherpesvirus nucleosides by varicella-zoster virus-specific enzymes[J]. Antimicrob Agents Chemother, 1996,40(4): 920-923.
3Niv D,Maltsman TA.Postherpectic neuralgia the never-ending challenge.Pain Pract,2005,5(4):327-340.
4Carcio H.Herpes zoster alert.Prevent shingles with vaccination and awareness.Adv Nurse Pract,2008,16(12):47-49.
5Izumi A.Varicella zoster virus infection in patients taking the TNFalpha inhibitor,etanercept:coincidence or causal? Hawaii Med J,2009,68(11):277-278.
